Israeli liver cancer drug success

Israel’s Can-Fite BioPharma has reported success in the Phase I/II clinical trial of its CF102 (Namodenoson) treatment for liver cancer (hepatocellular carcinoma or HCC). It was also successful in Phase I/II trials for treating Hepatitis C.

This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *